OPKO Health, Inc.

NASDAQ:OPK

Biotechnology

Healthcare
$1.69 +0.52%

+$0.01 today

Market cap
$1.25B
Beta
1.49
P/E (TTM)
-5.1
EPS (TTM)
-$0.28
52W Low $0.98High $1.60

Volume 3.06M

Average 2.59M

OPK Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

OPKO Health, Inc.NASDAQ: OPK

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.74M rose 4.5% year over year, ahead of the -2.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 6.2% from the prior quarter. Over 3 fiscal years it compounded at -16.7% a year.

Context

  • Stock-based compensation amounted to 1.8% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.5% holds above the trailing-twelve-month pace of -2.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.74M-6.2% QoQ
Last fiscal yearDec 2025
$10.71M-3.0% YoY
LTMMar 2026
$10.83M-2.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.5%——
1 year-3.0%——
3-year CAGR-16.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10.71M USD
Year-over-year change
-3.0%
4-year CAGR
-5.8%

Stock-Based Compensation vs competitors

How OPK compares with its peers on the latest reported figures

  • OPK's LTM Mar 2026 stock-based compensation of $10.83M is the 8th largest of the 11 companies compared; the peer median is $28.6M.
  • Its year-over-year change of -2.2% is the 5th highest of 10, against a peer median of -4.5%.
  • Stock-based compensation amounts to 1.9% of revenue for OPK, versus a peer median of 7.7%.
OPK Competitors Peer median
Stock-Based Compensation for OPK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$381.42M +21.6%+32.5%14.1%
GHGuardant Health, Inc.LTM Sep 2026$210.96M +32.4%+20.6%16.5%
CSTLCastle Biosciences, Inc.LTM Mar 2026$44.49M -8.9%+8.1%13.1%
MYGNMyriad Genetics, Inc.LTM Mar 2026$32.2M -31.9%-2.6%3.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$29.03M -33.3%+6.6%9.1%
NEONeoGenomics, Inc.LTM Jun 2026$28.16M -29.2%+18.8%3.7%
BLLNBillionToOne, Inc.LTM Jun 2026$25.54M ——6.4%
OPKOPKO Health, Inc.LTM Mar 2026$10.83M -2.2%-16.7%1.9%
PSNLPersonalis, Inc.LTM Mar 2026$9.76M -4.5%-21.4%15.1%
XGNExagen Inc.LTM Mar 2026$2.4M +47.3%-22.9%3.5%
MDXHMDxHealth S.A.FY2025$2.21M +28.2%+36.6%2.0%
Peer median (excluding OPK) $28.6M-4.5%+8.1%7.7%

Competitors are the stored peer set for OPK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.14M)(328.41M)(188.86M)(53.22M)(225.68M)
Depreciation & Amortization78.72M108.66M105.3M98.18M91.63M
Deferred Income Tax10.16M(74.41M)146K14.74M(15M)
Stock-Based Compensation13.63M18.51M11.41M11.05M10.71M
Change in Working Capital(20.48M)42.65M21.8M32.18M(41.18M)
Accounts Receivables5.23M128.6M3.41M(220K)30.21M
Inventory30.68M13.66M15.2M4.22M(4.12M)
Accounts Payables(10.85M)(9.39M)2.83M(20.66M)(14.22M)
Other Working Capital(45.55M)(90.22M)363K48.84M(53.06M)
Other Non-Cash Items(13.55M)137.8M22.01M(286.41M)976K
Operating Cash Flow38.34M(95.19M)(28.2M)(183.49M)(178.54M)
Capital Expenditures(32.16M)(24.58M)(16.28M)(25.01M)(12.28M)
Acquisitions (Net)(6M)(1.76M)(5M)00
Purchases of Investments00000
Sales of Investments8.08M115.42M364K166.6M52.18M
Other Investing Activities66.03M1.95M2.71M210.62M190.39M
Investing Cash Flow35.95M91.04M(18.2M)352.21M230.3M
Debt Repayment(11.24M)23.75M(11.03M)287.98M(70.76M)
Common Stock Issued0000(256K)
Common Stock Repurchased000(90.22M)(47.04M)
Dividends Paid00000
Other Financing Activities893K(774K)(272K)(13.59M)0
Financing Cash Flow(10.35M)22.97M(11.3M)184.17M(118.06M)
Effect of Forex Changes(1.44M)(339K)388K(3.16M)3.43M
Net Change in Cash62.5M18.48M(57.31M)349.73M(62.87M)
Free Cash Flow6.18M(119.77M)(44.47M)(208.5M)(190.82M)

OPKO Health, Inc.

NASDAQ:OPK

Intrinsic Alpha fair value

Locked

Current Price

$1.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.